Our company undertakes an interdisciplinary approach using big data analysis to produce working solutions for age-related eye diseases. Our primary disease of interest is Age-related macular degeneration (AMD). AMD is the leading cause of visual impairment and blindness in older adults and one of the most common causes of visual impairment worldwide. Vision Genomics, LLC is focused on operations a
nd development of its AMD Medicine drug discovery with a personalized medicine platform. AMD Medicine was developed using the advanced genomic and transcriptomic analysis algorithms already successfully used in cancer research and precision medicine in oncology. The AMD Medicine platform contains broad databases of gene expression, genetic and epigenetic data in ocular diseases as databases of drugs with known molecular targets and effects on gene expression in a variety of tissues and cell lines. It includes advanced parametric and machine learning algorithms that screen for drugs that minimize the difference between healthy and disease states while targeting signaling pathways that are pathologically activated or down regulated and accounting for pharmacogenomic effects. Our company focuses on development of geroprptectors for AMD using such interdisciplinary technology.
